Ubs Asset Management Americas Inc Karyopharm Therapeutics Inc. Transaction History

Ubs Asset Management Americas Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.84 - $3.92 $24,858 - $34,311	8,753 Added 10.56%	91,628 $356,000
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $26,915 - $64,358	10,853 Added 15.07%	82,875 $281,000
Q3 2022 Nov 14, 2022	BUY	$4.08 - $5.82 $3,064 - $4,370	751 Added 1.05%	72,022 $393,000
Q2 2022 Aug 12, 2022	BUY	$4.15 - $8.37 $37,976 - $76,593	9,151 Added 14.73%	71,271 $321,000
Q1 2022 May 16, 2022	SELL	$5.91 - $14.38 $174,941 - $425,662	-29,601 Reduced 32.27%	62,120 $457,000
Q4 2021 Feb 14, 2022	BUY	$5.21 - $8.61 $38,178 - $63,094	7,328 Added 8.68%	91,721 $589,000
Q2 2021 Aug 16, 2021	BUY	$8.11 - $11.11 $233,308 - $319,612	28,768 Added 51.72%	84,393 $870,000
Q1 2021 May 14, 2021	SELL	$9.85 - $17.69 $71,461 - $128,340	-7,255 Reduced 11.54%	55,625 $585,000
Q4 2020 Mar 01, 2021	BUY	$14.15 - $17.19 $178,544 - $216,903	12,618 Added 25.1%	62,880 $973,000
Q3 2020 Nov 13, 2020	SELL	$14.14 - $19.71 $24,052 - $33,526	-1,701 Reduced 3.27%	50,262 $733,000
Q2 2020 Aug 14, 2020	SELL	$16.6 - $25.25 $879 - $1,338	-53 Reduced 0.1%	51,963 $984,000
Q1 2020 May 15, 2020	SELL	$14.38 - $27.72 $189,240 - $364,795	-13,160 Reduced 20.19%	52,016 $999,000
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $101,936 - $217,235	11,044 Added 20.4%	65,176 $1.25 Million
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $153,702 - $321,798	27,156 Added 100.67%	54,132 $520,000
Q2 2019 Aug 15, 2019	BUY	$4.32 - $6.43 $58,626 - $87,261	13,571 Added 101.24%	26,976 $0
Q4 2018 Feb 13, 2019	BUY	$8.2 - $16.95 $109,920 - $227,214	13,405 New	13,405 $125,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $51.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.